Cervical Spinal Cord Injury

2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

VP
1 program
1
VX-210Phase 2/31 trial
Active Trials
NCT02669849Terminated70Est. Nov 2018
Lineage Cell Therapeutics
1 program
1
AST-OPC1Phase 1/21 trial
Active Trials
NCT02302157CompletedEst. Dec 2018
MicroTransponder
MicroTransponderTX - Austin
1 program
Active VNSN/A1 trial
Active Trials
NCT05601661CompletedEst. Aug 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Vertex PharmaceuticalsVX-210
Lineage Cell TherapeuticsAST-OPC1
MicroTransponderActive VNS

Clinical Trials (3)

Total enrollment: 70 patients across 3 trials

NCT02669849Vertex PharmaceuticalsVX-210

Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

Start: Jul 2016Est. completion: Nov 201870 patients
Phase 2/3Terminated
NCT02302157Lineage Cell TherapeuticsAST-OPC1

Dose Escalation Study of AST-OPC1 in Spinal Cord Injury

Start: Mar 2015Est. completion: Dec 2018
Phase 1/2Completed
NCT05601661MicroTransponderActive VNS

Safety and Feasibility of Paired Vagus Nerve Stimulation With Rehabilitation for Improving Upper Extremity Function in People With Cervical Spinal Cord Injury

Start: Jun 2023Est. completion: Aug 2025
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space